208 related articles for article (PubMed ID: 24837425)
1. Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine.
Klemettilä JP; Kampman O; Seppälä N; Viikki M; Hämäläinen M; Moilanen E; Leinonen E
Psychiatry Res; 2014 Aug; 218(3):277-83. PubMed ID: 24837425
[TBL] [Abstract][Full Text] [Related]
2. Association study of the HTR2C, leptin and adiponectin genes and serum marker analyses in clozapine treated long-term patients with schizophrenia.
Klemettilä JP; Kampman O; Seppälä N; Viikki M; Hämäläinen M; Moilanen E; Mononen N; Lehtimäki T; Leinonen E
Eur Psychiatry; 2015 Feb; 30(2):296-302. PubMed ID: 25284335
[TBL] [Abstract][Full Text] [Related]
3. Resistin as an inflammatory marker in patients with schizophrenia treated with clozapine.
Klemettilä JP; Kampman O; Seppälä N; Viikki M; Hämäläinen M; Moilanen E; Leinonen E
Nord J Psychiatry; 2017 Feb; 71(2):89-95. PubMed ID: 27658459
[TBL] [Abstract][Full Text] [Related]
4. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome.
Beumer W; Drexhage RC; De Wit H; Versnel MA; Drexhage HA; Cohen D
Psychoneuroendocrinology; 2012 Dec; 37(12):1901-11. PubMed ID: 22541717
[TBL] [Abstract][Full Text] [Related]
5. Association of plasma retinol-binding protein-4, adiponectin, and high molecular weight adiponectin with metabolic adversities in patients with schizophrenia.
Chen PY; Huang MC; Chiu CC; Liu HC; Lu ML; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1927-32. PubMed ID: 21840365
[TBL] [Abstract][Full Text] [Related]
6. Serum IL-1ra, a novel biomarker predicting olanzapine-induced hypercholesterolemia and hyperleptinemia in schizophrenia.
Lin Y; Peng Y; He S; Xu J; Shi Y; Su Y; Zhu C; Zhang X; Zhou R; Cui D
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):71-78. PubMed ID: 29410009
[TBL] [Abstract][Full Text] [Related]
7. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder.
Hanssens L; van Winkel R; Wampers M; Van Eyck D; Scheen A; Reginster JY; Collette J; Peuskens J; De Hert M
Schizophr Res; 2008 Dec; 106(2-3):308-14. PubMed ID: 18930377
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin.
Lu ML; Wang TN; Lin TY; Shao WC; Chang SH; Chou JY; Ho YF; Liao YT; Chen VC
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():47-50. PubMed ID: 25496829
[TBL] [Abstract][Full Text] [Related]
9. Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.
Kelly CW; McEvoy JP; Miller BJ
Schizophr Res; 2019 Jul; 209():193-197. PubMed ID: 31118157
[TBL] [Abstract][Full Text] [Related]
10. Association of adipokines with metabolic disorders in patients with schizophrenia: Results of comparative study with mental healthy cohort.
Tanyanskiy DA; Martynikhin IA; Rotar OP; Konradi AO; Sokolian NA; Neznanov NG; Denisenko AD
Diabetes Metab Syndr; 2015; 9(3):163-7. PubMed ID: 25952038
[TBL] [Abstract][Full Text] [Related]
11. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia.
Bai YM; Chen JY; Yang WS; Chi YC; Liou YJ; Lin CC; Wang YC; Lin CY; Su TP; Chou P
J Clin Psychiatry; 2007 Dec; 68(12):1834-9. PubMed ID: 18162013
[TBL] [Abstract][Full Text] [Related]
12. Adipokines, inflammatory mediators, and insulin-resistance parameters may not be good markers of metabolic syndrome after liver transplant.
Anastácio LR; de Oliveira MC; Diniz KG; Ferreira AM; Lima AS; Correia MI; Vilela EG
Nutrition; 2016 Sep; 32(9):921-7. PubMed ID: 27189907
[TBL] [Abstract][Full Text] [Related]
13. In vivo immunomodulatory effects of clozapine in schizophrenia.
Maes M; Bosmans E; Kenis G; De Jong R; Smith RS; Meltzer HY
Schizophr Res; 1997 Aug; 26(2-3):221-5. PubMed ID: 9323354
[TBL] [Abstract][Full Text] [Related]
14. Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment.
de Witte L; Tomasik J; Schwarz E; Guest PC; Rahmoune H; Kahn RS; Bahn S
Schizophr Res; 2014 Apr; 154(1-3):23-9. PubMed ID: 24582037
[TBL] [Abstract][Full Text] [Related]
15. Association of C-reactive protein, interleukin-1 receptor antagonist and adiponectin with the metabolic syndrome.
Saltevo J; Vanhala M; Kautiainen H; Kumpusalo E; Laakso M
Mediators Inflamm; 2007; 2007():93573. PubMed ID: 18288276
[TBL] [Abstract][Full Text] [Related]
16. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders.
Igue R; Potvin S; Bah R; Stip E; Bouchard RH; Lipp O; Gendron A; Kouassi E
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1695-8. PubMed ID: 21627977
[TBL] [Abstract][Full Text] [Related]
17. Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine.
O'Connell KE; Thakore J; Dev KK
Schizophr Res; 2014 Jun; 156(1):1-8. PubMed ID: 24742875
[TBL] [Abstract][Full Text] [Related]
18. [Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia].
Lü LX; Guo SQ; Chen W; Li Q; Cheng J; Guo JH
Di Yi Jun Yi Da Xue Xue Bao; 2004 Nov; 24(11):1251-4. PubMed ID: 15567770
[TBL] [Abstract][Full Text] [Related]
19. A novel biomarker of cardiometabolic pathology in schizophrenia?
Lee EE; Sears DD; Liu J; Jin H; Tu XM; Eyler LT; Jeste DV
J Psychiatr Res; 2019 Oct; 117():31-37. PubMed ID: 31276836
[TBL] [Abstract][Full Text] [Related]
20. Adipocytokines and the metabolic syndrome among older persons with and without obesity: the InCHIANTI study.
Stenholm S; Koster A; Alley DE; Visser M; Maggio M; Harris TB; Egan JM; Bandinelli S; Guralnik JM; Ferrucci L
Clin Endocrinol (Oxf); 2010 Jul; 73(1):55-65. PubMed ID: 19878507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
